CUE Cash-Secured Put Strategy
CUE (Cue Biopharma, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; CUE-103 a CUE-100 series Immuno-STAT targeting the KRAS G12V mutation, including colorectal carcinoma, lung cancer, and pancreatic cancer; CUE-200 that focuses on cell surface receptors, including CD80 and/or 4-1BBL to address T cell exhaustion associated with chronic infections; and CUE-300 and CUE-400 framework to target various autoimmune diseases. Cue Biopharma, Inc. has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for the development of Immuno-STATs focused on the field of oncology; and Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
CUE (Cue Biopharma, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $77.4M, a beta of 2.39 versus the broader market, a 52-week range of 4.98-41.42, average daily share volume of 758K, a public-listing history dating back to 2018, approximately 41 full-time employees. These structural characteristics shape how CUE stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 2.39 indicates CUE has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a cash-secured put on CUE?
A cash-secured put sells an out-of-the-money put while holding cash equal to the strike-times-100 obligation, keeping the premium when the underlying stays above the strike.
Current CUE snapshot
As of May 15, 2026, spot at $25.05, ATM IV 43.80%, IV rank 10.60%, expected move 12.56%. The cash-secured put on CUE below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this cash-secured put structure on CUE specifically: CUE IV at 43.80% is on the cheap side of its 1-year range, which means a premium-selling CUE cash-secured put collects less credit per unit of strike-width risk, with a market-implied 1-standard-deviation move of approximately 12.56% (roughly $3.15 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated CUE expiries trade a higher absolute premium for lower per-day decay. Position sizing on CUE should anchor to the underlying notional of $25.05 per share and to the trader's directional view on CUE stock.
CUE cash-secured put setup
The CUE cash-secured put below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With CUE near $25.05, the first option leg uses a $23.80 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed CUE chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 CUE shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Sell 1 | Put | $23.80 | N/A |
CUE cash-secured put risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Max profit equals premium times 100; max loss equals strike minus premium times 100 (at zero, assuming assignment). Breakeven is strike minus premium.
CUE cash-secured put payoff curve
Modeled P&L at expiration across a range of underlying prices for the cash-secured put on CUE. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use cash-secured put on CUE
Cash-secured puts on CUE earn premium while a trader waits to acquire CUE stock at a target strike below the current quote; most attractive when IV is rich and the trader is comfortable owning CUE.
CUE thesis for this cash-secured put
The market-implied 1-standard-deviation range for CUE extends from approximately $21.90 on the downside to $28.20 on the upside. A CUE cash-secured put lets a trader earn premium while waiting to acquire CUE at the strike price; the strategy is most attractive when the trader is comfortable holding the underlying at that level and IV is rich enough to compensate for the assignment risk. Current CUE IV rank near 10.60% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on CUE at 43.80%. As a Healthcare name, CUE options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to CUE-specific events.
CUE cash-secured put positions are structurally neutral to slightly bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. CUE positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move CUE alongside the broader basket even when CUE-specific fundamentals are unchanged. Short-premium structures like a cash-secured put on CUE carry tail risk when realized volatility exceeds the implied move; review historical CUE earnings reactions and macro stress periods before sizing. Always rebuild the position from current CUE chain quotes before placing a trade.
Frequently asked questions
- What is a cash-secured put on CUE?
- A cash-secured put on CUE is the cash-secured put strategy applied to CUE (stock). The strategy is structurally neutral to slightly bullish: A cash-secured put sells an out-of-the-money put while holding cash equal to the strike-times-100 obligation, keeping the premium when the underlying stays above the strike. With CUE stock trading near $25.05, the strikes shown on this page are snapped to the nearest listed CUE chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are CUE cash-secured put max profit and max loss calculated?
- Max profit equals premium times 100; max loss equals strike minus premium times 100 (at zero, assuming assignment). Breakeven is strike minus premium. For the CUE cash-secured put priced from the end-of-day chain at a 30-day expiry (ATM IV 43.80%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a CUE cash-secured put?
- The breakeven for the CUE cash-secured put priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current CUE market-implied 1-standard-deviation expected move is approximately 12.56%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a cash-secured put on CUE?
- Cash-secured puts on CUE earn premium while a trader waits to acquire CUE stock at a target strike below the current quote; most attractive when IV is rich and the trader is comfortable owning CUE.
- How does current CUE implied volatility affect this cash-secured put?
- CUE ATM IV is at 43.80% with IV rank near 10.60%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.